Abstract: A rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin, sugar alcohol (e.g., mannitol), and a flavorant and (b) an active therapeutic ingredient (ATI). Preferred rapidly infusing compositions are those formulated with a PDE5 inhibitor as the ATI. A method of administering an ATI such as a PDE5 inhibitor to a subject is also disclosed. The subject is administered the rapidly infusing composition via the oral mucosa to treat a condition responsive to inhibition of PDE5, for example, erectile dysfunction.

Abstract: The disclosure features novel methods of producing nucleic acid lipid nanoparticle (LNP) compositions employing a modifying agent after formation of a precursor nucleic acid lipid nanoparticle, the produced compositions thereof, and methods involving the nucleic acid lipid nanoparticles useful in the delivery of therapeutics and/or prophylactics, such as a nucleic acid, to mammalian cells or organs to, for example, to regulate polypeptide, protein, or gene expression.

Abstract: A method of treating autism spectrum disorder (ASD) in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof.

Abstract: A method of treating an autoimmune disease and/or inflammatory condition in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof. The autoimmune disease and/or inflammatory condition may include, inter alia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, type-I diabetes, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, and ulcerative colitis, including refractory diseases/conditions thereof.

Abstract: A preparation containing saxagliptin having improved stability and a method for producing the same are provided. According to an embodiment of the present invention, a preparation containing saxagliptin including a plain tablet part containing one or more first additive agent selected from a group consisting of D-mannitol, lactose, anhydrous lactose, and anhydrous dibasic calcium phosphate, the plain tablet part containing less than 35% by weight of crystalline cellulose with respect to 100% by weight of the plain tablet part, and a film coating part in contact with the plain tablet part and containing saxagliptin, a salt thereof, or a hydrate thereof, and a method for producing the same are provided.

Abstract: The invention encompasses a process for densifying co-precipitated material comprised of an active pharmaceutical ingredient and at least one stabilizing excipient using thin film evaporation, and the densified co-precipitates made thereby. Bulk density and flowability of co-precipitates can be increased by processing the co-precipitated material using thin film evaporation.

Abstract: Systems, methods, devices, and compounds for facilitating a capsule are provided. The capsule includes a first hollow body and a second hollow body configured to couple together, which collectively form an interior volume of the capsule. The capsule includes a divider that includes a base and a sidewall protruding from a first circumferential edge portion of the base. The sidewall includes an inner surface, an outer surface, and a second circumferential edge portion. The second circumferential edge portion is configured to continuously engage a unique circumferential surface of the capsule, which secures the divider within the interior volume of the capsule and forms at least two unique interior volumes based on a position of the t divider and the unique circumferential surface of the capsule. The capsule includes a plurality of pharmaceutical compositions, each of which occupies a unique interior volume in the at least two unique interior volumes.

Abstract: A dosage form for oral delivery of a therapeutic agent to a subject, the dosage form comprising: (i) a lipid nanocarrier formulation, the lipid nanocarrier formulation comprising the therapeutic agent, and lipids in the form of a mesophase; and (ii) an enteric coating encapsulating the lipid nanocarrier formulation.

Abstract: A dissolvable film delivery system formed by printing one or more layers of inks formulated to deliver specific ingredients and convey graphic imagery and textual information. The dissolvable film is printed to convey a graphic image or textual message using a single printed layer. The dissolvable film may further be printed using multiple layers of inks that incorporate different ingredients into the overall graphic design to achieve a desired effect from incorporated layers. The dissolvable graphic is further printed in layers to achieve a method of encapsulation allowing for a sequential delivery of ingredients comprising flavors and dosage of active ingredients.

Abstract: The present invention relates to a sterile gel formulation suitable for use in filling a wound cavity and delivering an active ingredient thereto, the gel further having a pH range of 4.5 to 8.5, low bioadhesive strength and cohesive integrity and being formed from a polymer selected from among the group consisting of poly(vinyl) alcohol (PVA) polymer and a PVA-polyvinyl acetate copolymer, a cross-linker being a salt form of boron that produces borate ions in aqueous solution, at least one compound which has a beneficial effect as an active ingredient in the wound and at least one modulator, the modulator being a low molecular weight species that is capable of binding borate or PVA in aqueous solution through a mono-diol or di-diol formation and reduces the pH of PVA-borate hydrogels; wherein the gel is heat and/or gamma sterilised and contains less than 5% acetic acid and the polymer has a degree of hydrolysis of between 98% and 100% and a molecular weight of from 100,000 to 300,000 Daltons.

Abstract: Disclosed herein are compositions and methods for delivering cannabidiol to subject in need of hypertension treatment. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering the cannabidiol-containing compositions.

Abstract: Disclosed herein are compositions and methods for delivering cannabidiol to subject in need of hypertension treatment. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering the cannabidiol-containing compositions.

Abstract: Benzaldehyde (C6H5CHO), for example in a form extracted from a pit or seed of a plant of the Rosales order, in a solution of water wherein the benzaldehyde comprises at least 0.1%, and in some embodiments 3%-7% by volume of the solution, and in yet other embodiments, about 5% is used as a food preservative, an animal feed additive, a treatment and/or preventative treatment for covid-19 coronavirus infections.

Abstract: A method of extracting shikonin derivatives from Arnebia decumbens roots can include powdering the roots of Arnebia decumbens and extracting shikonin derivatives from the powder using isooctane. The shikonin derivatives can include four compounds: deoxyshikonin (compound B); shikonin-isovalerate (compound C); acetylshikonin (compound D); and shikonin (compound E). Acetyl-shikonin (compound D) and shikonin (compound E) can be used to treat stomach ulcers and diabetic ulcers.

Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.

Abstract: Disclosed are pharmaceutical compositions having a portion of ketamine and/or aspirin for intraoral release and another portion of ketamine and/or aspirin for gastrointestinal release. The disclosed formulations and related administration approaches improve the bioavailability and efficacy of oral ketamine.

Abstract: The present disclosure provides a method for treating alcohol use disorder (AUD) and associated symptoms to a subject in need thereof by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutically acceptable salt comprises a cyclobenzaprine acid salt.

Abstract: This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prologation.

Abstract: The disclosure provides oral cystamine formulations, methods, and kits useful for treating cystinosis and cysteamine and cystamine sensitive diseases or disorders. The formulations provide a set of varying release compositions that improve the quality of life and offer reduced side-effects.

Abstract: The present invention discloses a non-aqueous gel composition which is useful for administration of pharmaceutically active agents, in particular for transtympanic administration of pharmaceutically active agents. The non-aqueous gel composition comprises castor oil, present in an amount from 85 to 95% by weight, based on the total weight of the composition, an oleoyl macrogolglyceride, preferably Labrafil®, present in an amount from 2 to 6 by weight, based on the total weight of the composition, at least one thickener, preferably silicon dioxide, more preferably colloidal silicon dioxide, present in an amount from 1 to 6% by weight, based on the total weight of the composition, and wherein the viscosity of the composition at a temperature of 25° C. is between 1400 and 2400 mPas, preferably between 1400 and 1800 mPas.

Abstract: The present invention relates to the treatment of leaky gut. More particularly, the invention provides compounds, and compositions thereof, for use in methods for the treatment of leaky gut and in methods for the treatment of a subclinical increase in gut permeability. The invention further provides compounds, and compositions thereof, for use in methods for the treatment of leaky gut syndrome. The invention further provides compounds, and compositions thereof, for use in methods for the improvement of at least one symptom associated with leaky gut syndrome. The present invention also relates to a method for treatment of leaky gut, a method for treatment of leaky gut syndrome, and a method for improving at least one symptom associated with leaky gut syndrome.

Abstract: Disclosed herein are pharmaceutical compositions comprising an azobenzene photoswitch compound and an alkylated cyclodextrin. Such compositions may be administered to the eye to treat a variety of retina disorders.

Abstract: Pharmaceutical compositions comprising suramin and methods of preparing synthetic intermediates useful for the preparation of suramin are described herein.

Abstract: The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl? co-transporter or GABAA receptor.

Abstract: Disclosed herein are methods and pharmaceutical compositions to treat systemic inflammatory response syndrome. In some embodiments, a pharmaceutical composition disclosed herein comprises at least two short chain fatty acids or pharmaceutically-acceptable salts thereof in a ratio of at least 4:1. In some embodiments, administering a pharmaceutical composition of the disclosure reduces a level of a cytokine in the subject.

Abstract: The present disclosure describes compositions and methods for treating hepatitis B virus-associated hepatocellular carcinoma. Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC). The HBV encoded oncoprotein, HBx, alters the expression of host genes and the activity of multiple signal transduction pathways. Short chain fatty acids can be used to delay or block the progression of chronic liver disease to HCC by targeting functions associated with HBx.

Abstract: The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a pregnant mother of a prenatal subject in need thereof, and to pharmaceutical DIPTA formulations for administration to the pregnant mother of a prenatal subject in need thereof.

Abstract: The present subject matter is directed to pharmaceutical compositions comprising 3,5-diiodothyropropionic acid, or a salt thereof, and one or more pharmaceutically acceptable excipients. The present subject matter is further directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering to a subject in need thereof one or more compositions comprising 3,5-diiodothyropropionic acid, or salt thereof, and one or more pharmaceutically acceptable excipients.

Abstract: The present subject matter is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, wherein the DITPA administration reduces triiodothyronine (“T3”) serum levels to normal, increases T3 brain levels to normal, and maintains normal serum levels of thyroxine (T4) and thyroid stimulating hormone (TSH). The subject may be a child or an adult.

Abstract: The present invention relates to an antiviral composition for Betacoronavirus comprising rhein and meclofenamic acid as active components. When the antiviral composition of the present invention is used, an antiviral effect is demonstrated whereby the viral RNA level of SARS-CoV-2 and HCoV-OC43 is suppressed, and thus it is possible to treat or prevent COVID-19 or a cold.

Abstract: Methods and compositions including (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided for use in treating cancer and inhibiting cancer proliferation and metastasis.

Abstract: Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

Abstract: Provided are methods for enhancing cellular metabolism and cellular repair in a tissue of a subject in need thereof. The method includes administering a dose of at least an N-methyl-D-aspartate receptor glycine site agonist, an N-methyl-D-aspartate receptor REDOX site agonist, and a nuclear factor erythroid 2-related receptor agonist; wherein the dose induces cellular metabolic fitness activation in the subject. The method for enhancing cellular metabolism and cellular repair synergistically modulates a positive-feedback signal-amplification cycle comprising NMDAR and NRF2 in cells, which, in turn, promotes cellular metabolic fitness (CMF) in a tissue of a subject in need thereof.

Abstract: The present specification discloses one or more anti-oncogenic phytochemicals, extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals disclosed herein, methods of preparing extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals, extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals prepared according to methods disclosed herein, and methods and uses for treating a neoplasm or a cancer using one or more anti-oncogenic phytochemicals as well as extracts, pharmaceutical compositions and medicaments comprising one or more anti-oncogenic phytochemicals disclosed herein.

Abstract: The present inventive concept provides methods for treating or preventing ulcerative colitis including administering a therapeutically effective amount of dihydro-lipoic acid, or a derivative, pharmaceutically acceptable salt, metabolite, solvate, prodrug, enantiomer, or polymorph of the dihydro-lipoic acid. The inventive concept further provides compositions and formulations for use in the methods described herein.

Abstract: Malaria remains a major concern of morbidity and mortality. Despite treating infected individuals with artemisinin-based combination therapies (ACTs), cerebral and severe malaria cause enormous mortality in children and adults. The only treatment option is parenteral administration of artemisinin or quinine with supportive symptomatic therapies. However, the fatality rate remains high despite parasite clearance emphasizing the need of adjunct therapy to prevent malaria mortality. In this invention, heme synthesized in the malaria parasite is shown to be associated with parasite virulence, disease severity and cerebral pathogenesis. Parasite heme enhances the formation of hemozoin—a parasite molecule associated with cerebral and severe malaria. Griseofulvin prevents experimental cerebral malaria (ECM) by inhibiting parasite heme synthesis and hemozoin formation, without affecting parasite growth. Griseofulvin exhibits synergy with arteether—the principal component of ACTs and prevents ECM.

Abstract: This application provides the use of zanamivir in the preparation of drugs for the treatment or prevention of pre-eclampsia and the corresponding drugs and therapeutic methods; Zanamivir is effective in improving the symptoms of hypertension, proteinuria, elevated creatinine, neuraminidase and sialic acid in pre-eclampsia, increasing NO levels; and improving pregnancy outcomes. The combination of zanamivir and hydroxyprogesterone caproate showed superior results.

Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.

Abstract: The present disclosure relates to methods of treating dry age-related macular degeneration (dry AMD), comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein.

Abstract: The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

Abstract: The invention provides small-molecule inhibition of GSK-3 to increase efficacy of ICB and improve response in patients with microsatellite stable colorectal cancer, and possibly other tumor types. These results demonstrate 9-ING-41 in combination with ?PD-1/PD-L1 therapy.

Abstract: A system and method for delivering psilocin or a prodrug of psilocin to a mammal. The system includes a water-soluble mass to be maintained in contact with a mucosal area of the mammal. The mass contains an active ingredient. Active ingredients include psilocin or a prodrug of psilocin. Menthol, L-arginine, and the active ingredient are distributed in the water-soluble mass.

Abstract: The present disclosure relates to compositions, systems, and methods for treating cancer. In particular, the present disclosure relates to compositions, systems, and methods for characterizing and treating prostate cancer (e.g., castration-resistant prostate cancer).

Abstract: A method of treating acute kidney injury in a patient is provided, including administering to the patient a 5-HT3-targeting drug, the 5-HT3A-targeting drug, or the pharmaceutically-acceptable salt or solvate of a 5-HT3-targeting drug or a 5-HT3A-targeting drug, in an amount effective to treat acute kidney injury in the patient.

Abstract: The present disclosure provides methods for treating an individual in need of a composition having a compound having the following structure: Formula (I) The methods may be used to disrupt mitochondrial unfolded protein response. In various examples, a compound of the composition binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 to ClpP, thus interrupting the mitochondrial unfolded protein response. For example, the composition may be used as a therapeutic approach for treating advanced prostate cancers that are no longer sensitive to AR targeted therapies.

Abstract: Substituted tetrazole derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

Abstract: Methods of treating or preventing a disease resulting from a respiratory syncytial virus (RSV) infection in a human subject is disclosed. The methods disclosed include administering to the human subject a compound of Formula (I), or pharmaceutical composition including a compound of Formula (I). In certain embodiments, the compound is celgosivir.

Abstract: Combination compositions exhibiting anti-viral activities are provided, which are based on unique combinations of polyphenol zinc ionophores. Exemplary compositions comprise combinations of flavonoid zinc ionophores selected from EGCG, quercetin and taxifolin, preferably further comprising a zinc compound and a copper compound. The compositions preferably contain additional ingredients to further enhance the anti-viral effect of the composition and/or to provide additional benefits.

Abstract: The present disclosure is directed toward uses of compound 1 (or its stereoisomers) and compositions and/or dosage forms containing compound 1: or a pharmaceutically acceptable salt thereof. Some uses of Compound 1 and/or its stereoisomers include treating a variety of diseases and disorders, including pain, depression, and schizophrenia. In some embodiments, Compound 1 and/or its stereoisomers may be useful in the treatment of a substance use disorder while inducing fewer withdrawal symptoms than a standard-of-care opioid addiction treatment.

Abstract: Disclosed are methods for the treatment of cystic fibrosis, methods of increasing airway surface liquid pH, methods of enhancing respiratory defense, and methods of testing a compound of interest for use as a treatment for cystic fibrosis.